Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: A quasi-experiment

Journal of Clinical Psychiatry

Volumn 71, Issue 10, 2010, Pages 1371-1378

  Brooks, Adam C ^a,b   Comer, Sandra D ^b,c   Sullivan, Maria A ^b,c   Bisaga, Adam ^b,c   Carpenter, Kenneth M ^b,c   Raby, Wilfrid M ^b,c   Yu, Elmer ^d,e   O'Brien, Charles P ^d,e   Nunes, Edward V ^b,c  

^a TREATMENT RESEARCH INSTITUTE   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^c College of Physicians and Surgeons of Columbia University ^*  (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEPOTREX; NALTREXONE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; COGNITIVE THERAPY; CONTROLLED STUDY; DRUG DOSAGE FORM COMPARISON; DRUG MEGADOSE; FEMALE; HEROIN DEPENDENCE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; QUASI EXPERIMENTAL STUDY; SUSTAINED RELEASE FORMULATION;

ADMINISTRATION, ORAL; ADULT; COGNITIVE THERAPY; DELAYED-ACTION PREPARATIONS; FEMALE; HEROIN DEPENDENCE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78149301618     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.09m05080ecr     Document Type: Article

References (23)

1. Rounsaville BJ. Can psychotherapy rescue naltrexone treatment of opioid addiction? In: Onken LS, Blaine JD, Boren JJ, eds. NIDA Research Monograph Series 150: Integrating Behavioral Therapies With Medications in the Treatment of Drug Dependence. Bethesda, MD: US Dept of Health and Human Services; 1995:37-52.
2. Carpenter KM, Jiang H, Sullivan MA, et al. Betting on change: modeling transitional probabilities to guide therapy development for opioid dependence. Psychol Addict Behav. 2009;23(1):47-55. doi:10.1037/a013049 PubMed
3. Grabowski J, O'Brien CP, Greenstein RA. Effects of contingent payment on compliance with a naltrexone regimen. Am J Drug Alcohol Abuse. 1979;6(3):355-365. doi:10.3109/09529790901724
4. Carroll KM, Ball SA, Nich C, et al. Targeting behavioral therapies to enhance naltrexone treatment of opioid dependence: efficacy of contingency management and significant other involvement. Arch Gen Psychiatry. 2001;58(8):755-761. doi:10.101/archpsyc.58.8.75 PubMed
5. Preston KL, Silverman K, Umbricht A, et al. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend. 1999;54(2):127-135. doi:10.1016/S0376-8716(98)0152-5 PubMed
6. Nunes EV, Rothenberg JL, Sullivan MA, et al. Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness? Am J Drug Alcohol Abuse. 2006;32(4):503-517. doi:10.1080/09529060918973 PubMed
7. Fals-Stewart W, O'Farrell TJ. Behavioral family counseling and naltrexone for male opioid-dependent patients. J Consult Clin Psychol. 2003;71(3):432-442. doi:10.1037/02-06X.71.3.432 PubMed
8. Rothenberg JL, Sullivan MA, Church SH, et al. Behavioral naltrexone therapy: an integrated treatment for opiate dependence. J Subst Abuse Treat. 2002;23(4):351-360. doi:10.1016/S0740-5472(02)0301-X PubMed
9. Hulse GK, Basso MR. The association between naltrexone compliance and daily supervision. Drug Alcohol Rev. 2000;19(1):41-48. doi:10.1080/0959523096138
10. Johansson BA, Berglund M, Lindgren A. Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review. Addiction. 2006;101(4):491-503. doi:10.1/j.1360-043.206.01369.x PubMed
11. Comer SD, Sullivan MA, Yu E, et al. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63(2):210-218. doi:10.101/archpsyc.63.2.210 PubMed
12. Foster J, Brewer C, Steele T. Naltrexone implants can completely prevent early (1-month) relapse after opiate detoxification: a pilot study of two cohorts totalling 101 patients with a note on naltrexone blood levels. Addict Biol. 2003;8(2):211-217. doi:10.1080/13562103101746 PubMed
13. Colquhoun R, Tan DYK, Hull S. A comparison of oral and implant naltrexone outcomes at 12 months. J Opioid Manag. 2005;1(5):249-256. PubMed
14. Carreño JE, Alvarez CE, Narciso GI, et al. Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence. Addict Biol. 2003;8(4):429-438. doi:10.1080/13562103101646402 PubMed
15. Reece AS. Psychosocial and treatment correlates of opiate free success in a clinical review of a naltrexone implant program. Subst Abuse Treat Prev Policy. 2007;2:35. doi:10.186/1747-597X-2-35 PubMed
16. Krupitsky EM, Zvartau E, Egorova V, et al. Double blind randomized placebo controlled study of effectiveness of implantable naltrexone (Prodetoxone) for treatment of heroin addiction: interim analysis. Presented at the 70th Annual Scientific Meeting of the College on Problems of Drug Dependence; June 14-19, 2008; San Juan, Puerto Rico.
17. Comer SD, Collins ED, Kleber HD, et al. Depot naltrexone: long-lasting antagonism of the effects of heroin in humans. Psychopharmacology (Berl). 2002;159(4):351-360. doi:10.107/s0213010909 PubMed
18. Williams JBW. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry. 1988;45(8):742-747. PubMed
19. Marlatt GA, Gordon JR. Relapse Prevention and Maintenance Strategies in the Treatment of Addictive Behaviors. New York, NY: Guilford Press; 1985.
20. Carroll KM. A Cognitive-Behavioral Approach: Treating Cocaine Addiction. NIDA Therapy Manuals for Drug Addiction; Bethesda, MD: US Dept of Health and Human Services; 1998.
21. Galanter M. Network therapy for addiction: a model for office practice. Am J Psychiatry. 1993;150(1):28-36. PubMed
22. Higgins ST, Delaney DD, Budney AJ, et al. A behavioral approach to achieving initial cocaine abstinence. Am J Psychiatry. 1991;148(9):1218-1224. PubMed
23. Carroll KM, Nuro KR, O'Malley SS. Compliance Enhancement: A Manual for the Clinical Management of Drug-Dependent Patients. New Haven, CT: Yale University School of Medicine, Psychotherapy Development Center; 1999.